Dr Allan Baxter joins Ascletis as chief strategy officer
This article was originally published in Scrip
Dr Allan Baxter, formerly senior vice-president and global head of medicines development at GlaxoSmithKline, has joined US/China-based Ascletis as chief strategy officer. Dr Baxter has been an advisor to Ascletis since its founding. He is currently chairman of Stevenage Bioscience Catalyst, and of the Wellcome Trust's Seeding Drug Discovery Funding Committee, as well as a non-executive director of Human Genome Sciences and Vernalis.